Compare Gitlab Inc (GTLB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Viatris Inc — how do they compare? Gitlab Inc trades at $40.65 (market cap $7.11B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.6× Gitlab Inc's market cap, and Viatris Inc pays a 2.95% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | VTRS | |
|---|---|---|
Market Cap | $7.11B | $18.69B |
Sector | Technology | Health |
52-Week High | $51.04 | $17.86 |
52-Week Low | $19.42 | $9.49 |
Enterprise Value | $5.85B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $40.93, up 0.49% today, with a bullish technical signal from moving averages but overbought RSI readings above 90. The company reported strong revenue growth, reaching $759 million in 2025, and has beaten EPS estimates for three consecutive quarters. Recent news highlights its leadership in DevSecOps and AI-driven platform enhancements, including the launch of GitLab 19.2 and a collaboration with Google Cloud.
Outlook remains mixed; analyst consensus is cautious with a $32.92 price target below the current price, citing high valuation multiples like a P/E of 521.22. Risks include persistent negative cash flow and profitability challenges, though growth in AI and enterprise adoption offers long-term potential. Investors should weigh high valuation against robust revenue expansion and market position.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
